Neutralizing activity of saliva against cytomegalovirus

Clinical and Vaccine Immunology

Volumn 18, Issue 9, 2011, Pages 1536-1542

  Saccoccio, Frances M ^a   Gallagher, Mary K ^a   Adler, Stuart P ^a   McVoy, Michael A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CELL TYPE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; INNATE IMMUNITY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN INDUCTION; SALIVA ANALYSIS; SEROLOGY; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD DAY CARE CENTERS; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; IMMUNOGLOBULIN G; MALE; SALIVA;

EID: 80052492990     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05128-11     Document Type: Article

References (28)

1. Adler, B., et al. 2006. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J. Gen. Virol. 87:2451-2460.
2. Adler, S. P., and B. Marshall. 2007. Cytomegalovirus infections. Pediatr. Rev. 28:92-100. (Pubitemid 46495837)
3. Adler, S. P., et al. 1995. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of child-bearing age. J. Infect. Dis. 171:26-32. (Erratum, 171:1080.)
4. Arvin, A. M., P. Fast, M. Myers, S. Plotkin, and R. Rabinovich. 2004. Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39:233-239. (Pubitemid 38971495)
5. Cui, X., B. P. Meza, S. P. Adler, and M. A. McVoy. 2008. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760-5766.
6. Dollard, S. C., S. D. Grosse, and D. S. Ross. 2007. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol. 17:355-363. (Pubitemid 47425872)
7. Gerna, G., et al. 2008. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol. 89:853-865.
8. Granade, T. C., et al. 2002. Influence of host factors on immunoglobulin G concentration in oral fluid specimens. Clin. Diagn. Lab. Immunol. 9:194-197. (Pubitemid 34084301)
9. Hahn, G., et al. 2004. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78:10023-10033. (Pubitemid 39187120)
10. Jacobson, M. A., et al. 2009. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 27:1540-1548.
11. Macagno, A., et al. 2010. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84:1005-1013.
12. Marshall, B. C., and S. P. Adler. 2003. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: A live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). Viral Immunol. 16:491-500. (Pubitemid 38036776)
13. Mortimer, P. P., and J. V. Parry. 1991. Non-invasive virological diagnosis: Are saliva and urine specimens adequate substitutes for blood? Rev. Med. Virol. 1:73-78.
14. Pass, R. F., et al. 2009. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360:1191-1199.
15. Patrone, M., et al. 2005. Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J. Virol. 79:8361-8373. (Pubitemid 40853539)
16. Ryckman, B. J., et al. 2008. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 82:60-70. (Pubitemid 350309123)
17. Saccoccio, F. M., et al. 2011. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 29:2705-2711.
18. Shen, S., S. Wang, W. J. Britt, and S. Lu. 2007. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine 25:3319-3327. (Pubitemid 46534014)
19. Shimamura, M., M. Mach, and W. J. Britt. 2006. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing anti-body response. J. Virol. 80:4591-4600.
20. Stratton, K. R., S. J. Durch, and R. S. Lawrence (ed.). 2000. Vaccines for the 21st century: a tool for decisionmaking. National Academy Press, Washington, DC.
21. Tamura, T., S. Chiba, Y. Chiba, and T. Nakao. 1980. Virus excretion and neutralizing antibody response in saliva in human cytomegalovirus infection. Infect. Immun. 29:842-845. (Pubitemid 10009280)
22. Waissbluth, J. G., and M. J. Langman. 1971. ABO blood groups, secretor status, salivary protein, and serum and salivary immunoglobulin concentrations. Gut 12:646-649.
23. Wang, D., and T. Shenk. 2005. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 79:10330-10338. (Pubitemid 41098573)
24. Wang, D., and T. Shenk. 2005. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. U. S. A. 102:18153-18158. (Pubitemid 41798517)
25. Wang, J. B., and S. P. Adler. 1996. Salivary antibodies to cytomegalovirus (CMV) glycoprotein B accurately predict CMV infections among preschool children. J. Clin. Microbiol. 34:2632-2634. (Pubitemid 26307833)
26. Wang, J. B., et al. 1996. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J. Infect. Dis. 174:387-392. (Pubitemid 26251427)
27. Wang, J. B., and M. A. McVoy. 2008. Mutagenesis of the murine cytomegalovirus M56 terminase gene. J. Gen. Virol. 89:2864-2868.
28. Wilms, I. R., A. M. Best, and S. P. Adler. 2008. Cytomegalovirus infections among African-Americans. BMC Infect. Dis. 8:107.